Dosage Comparison: BPC-157 vs TB-500
The dosing philosophy differs fundamentally between these two peptides. BPC-157 has a short half-life and requires daily administration. TB-500 has a long half-life and uses a loading/maintenance approach. The table below provides a side-by-side comparison. Lo
This comparison does not assign a generated winner or score.
- The dosing philosophy differs fundamentally between these two peptides. BPC-157 has a short half-life and requires daily administration. TB-500 has a long half-life and uses a loading/maintenance approach. The table below provides a side-by-side comparison.
- Loading dose
- Not required
- 5-10 mg/week for 4-6 weeks
- 2.5-5 mg/week (maintenance)
- Severe injury dose
- 500 mcg/day
- 10 mg/week (loading)
- Mild injury dose
- 250 mcg/day
- 5 mg/week (loading)
- Frequency
- 1-2x daily
- 2-3x weekly (loading), 1-2x weekly (maintenance)
- Cycle length
- 4-8 weeks
- 8-12 weeks total
- Reconstitution
- 5 mg vial + 2.5 mL bac water = 2 mg/mL
- 5 mg vial + 2 mL bac water = 2.5 mg/mL
- Injection route
- Subcutaneous (near injury) or oral
- Subcutaneous (abdomen or thigh)
- Units per dose
- 12.5-25 units (at 2 mg/mL on insulin syringe)
- 100 units / 1 mL (at 2.5 mg/mL for 2.5 mg)
- Why BPC-157 needs daily dosing. Its half-life is roughly 4 hours. By the 8-hour mark, plasma levels have dropped to about 25% of peak. Daily injections maintain therapeutic concentrations at the injury site. Some users split the daily dose into two injections (morning and evening) for more stable levels.
- Why TB-500 uses loading/maintenance. Its 7-10 day half-life allows tissue levels to accumulate over weeks. The loading phase saturates the body's repair machinery. Skipping the loading phase is the most common TB-500 dosing mistake. Users who start at maintenance doses (2.5 mg/week) often see no results for 6-8 weeks, then assume the peptide is ineffective.
- Use the peptide dosage chart for cross-reference with other compounds, and the peptide reconstitution calculator for exact mixing volumes.